欧美一区二区精品少妇,日韩熟女av一二三区免费看,午夜色啪久久久久久性,av中文字幕不卡无码

訂購信息
上海拜力生物科技公司
Tel:400-968-7988    021-33779008
WIESLAB? Complement System Classical Pathway - RUO Svar Life Science
品牌:Svar Life Science
貨號(hào):COMPLCP310RUO
規(guī)格:96 wells
貨期:現(xiàn)貨
應(yīng)用: 點(diǎn)擊這里給我發(fā)消息  咨詢客服

商品詳情 參考文獻(xiàn) 相關(guān)資料

WIESLAB® Complement System Classical Pathway - RUO

COMPLCP310RUO

The Wieslab® Complement System Classical Pathway is an enzyme immunoassay for the qualitative and/or semi-quantitative determination of functional classical complement pathway and determination of complement deficiencies in human serum. Non-human primate and swine samples can also be assayed with Wieslab® Complement System Classical Pathway.

The Wieslab Complement System Classical Pathway assay combines the specific activation of the pathway with the use of labeled antibodies specific for a neoepitope of the terminal complement complex, C5b-9, produced as the result of complement activation. The amount of complement activation can be expressed either in a qualitative way relative the value of a positive control or in a semi-quantitative way using a calibrator curve derived from a separate lyophilized activity control. 

The? Wieslab Complement assays have been published as useful tools in evaluation of complement therapeutics, in clinic, clinical trials and in drug development.

Product code COMPLCP310RUO
Size 96 wells
Technology ELISA
Read-out of results Qualitative, Semi-quantitative
Assay time 2h
Detection system ALP/pNPP read at 405 nm
Regulatory status Research Use Only
熱銷產(chǎn)品
熱銷產(chǎn)品排行榜
  • 關(guān)于我們
  • 購物流程
  • 支付方式
  • 配送方式

請打開QQ掃碼聯(lián)系
Copyright@ 2003-2024  進(jìn)口試劑采購網(wǎng)版權(quán)所有     

BIOLEAF熱搜   BIOLEAF試劑盒   BIOLEAF ELISA   BIOLEAF試劑   BIOLEAF品牌   BIOLEAF抗體   BIOLEAF耗材   BIOLEAF小儀器

sitemap   細(xì)胞庫查詢   危險(xiǎn)品圖標(biāo)

本公司網(wǎng)站所展示銷售的產(chǎn)品僅供科研!

         滬ICP備08023583號(hào)-6     
產(chǎn)品咨詢
QQ掃碼溝通
在線客服
服務(wù)電話
400-968-7988
掃碼關(guān)注
微信公眾號(hào)二維碼

滬公網(wǎng)安備 31011202007338號(hào)

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |